2026-02-26 マックス・プランク研究所
In addition to brain imaging, laboratory analysis of cerebrospinal fluid is important for the diagnosis of multiple sclerosis (MS). In this study, proteomic analysis of this fluid has revealed a set of markers that better distinguishes MS from related inflammatory diseases in subjects that are negative for oligoclonal bands, a typical marker for MS. © TUM, adapted by MPI of Biochemistry
＜関連情報＞
- https://www.mpg.de/26198828/0226-bioc-new-diagnostic-markers-for-ms-discovered-in-csf-153945-x
- https://www.cell.com/cell/fulltext/S0092-8674(26)00104-2
神経疾患を対象とした大規模プロテオミクスにより、多発性硬化症のバイオマーカーパネルと標的が明らかになった Large-scale proteomics across neurological disorders uncovers biomarker panel and targets in multiple sclerosis
Jakob Maximilian Bader ∙ Christine Makarov ∙ Sabrina Richter ∙ … ∙ Christiane Gasperi, ∙ Bernhard Hemmer ∙ Matthias Mann
Cell Published:February 25, 2026
DOI:https://doi.org/10.1016/j.cell.2026.01.017
Highlights
- CSF proteomics of 5,000 samples across neurological disorders quantifies 1,500 proteins per sample
- Dominant signatures for blood-CSF barrier impairment, age, and sex
- CSF proteome-based donor staging correlates with MS disability and progression
- Targeted assay for 22 CSF markers aiding differential diagnosis of OCB-negative MS
Summary
Cerebrospinal fluid (CSF) is central to neurological diagnostics, yet biomarkers are lacking for many clinical needs. To enable its large-scale proteomic characterization, we developed a high-throughput mass spectrometry workflow quantifying approximately 1,500 proteins per CSF sample across 5,000 individuals, covering a spectrum of neurological disorders. This revealed proteomic alterations associated with blood-CSF barrier impairment, age, and sex, enabling deconvolution of shared and disease-specific signatures. We then focused on multiple sclerosis (MS), using an improved analytical technology that quantified 2,100 proteins per sample. From these data, we derived a 22-protein panel that distinguished MS from related inflammatory diseases and outperformed established markers in challenging cases. A targeted mass spectrometry assay using isotope-labeled standards validated this panel in an independent cohort, offering a clinically compatible format. Additionally, we highlight proteins of therapeutic interest and demonstrate proteome-based staging of individuals along the relapsing-progressive MS spectrum, which correlates with clinical outcomes.
